MoffittRadOnc
@MoffittRadOnc
Product of your friendly local USF Moffitt Cancer Center Radiation Oncology Residents. Highlighting departmental news, successes, research, events.
#hncsm tumor board❓- what is benefit of concurrent adjuvant chemo in pts w minor (<2mm) ENE? In this multi-inst RR, adjuvant chemo: 🔘 ❌ ⬆️ LRC, DFS, OS for Minor ENE 🔘 ✅ ⬆️ DFS, OS for Major ENE 🔘 ☢️ #radonc ⬆️ DFS for Minor ENE ja.ma/4kMfcOB
Rising PGY-5s and anyone interested, we have a 5th HN rad onc position @MoffittNews. If interested in joining a busy team, including me, Dr. M Echevarria, @BeekeepRadOnc, and @RadOncDoc_Niema, reach out and can chat about the position.
Moffitt GME Graduation - 46 graduates - congrats to all of you! Good luck and thank you for the years of incredible patient care, ground breaking research and being an integral part of the team. @MoffittNews
Congratulations to our Graduating Medical and Physics Residents! (Dr. Bryant, Dr. Cruz-Chamorro and Dr. Koo). We are so proud of you and know you will go onto great things! @JMBryantMD @RCruzChamorro @JessicaFrakesMD @EvanWuthrick @KOSJ12 @MoffittRadOnc @MoffittNews #radonc
A multi-institutional phase II trial revealed SBRT and atezolizumab was well tolerated in stage IV cervical cancer with responses in PD-L1 negative tumors. Read it in the #RedJournal. @KAhmedMD @RMWenham @MoffittRadOnc @MoffittGynOnc #radonc tinyurl.com/redahmed
Congratulations to our graduating chief residents for passing their clinical boards!! 🎉💯 @JMBryantMD @RCruzChamorro
From #ASCO25: Kamran Ahmed, MD (@KAhmedMD) highlights results from a phase II trial of SBRT + atezolizumab in metastatic cervical cancer, showing promising responses even in PD-L1 negative tumors. #MoffittASCO25
Critical question for C-POST. Without an OS benefit (and no real space between the curves currently), should cemiplimab be reserved for salvage?
Forest plot was pretty boring… pretty-much everyone benefitted, including CPS < 1%. Quality-of-life was the same in both arms, but patients presumably didn’t answer at recurrence. And the impact of recurrence is critical, because there was no difference in OS. Nada:
Results from our Ph II multi-institutional study now out in @IJROBP redjournal.org/article/S0360-… Overall & objective responses noted in PD-L1 neg metastatic cervical ca with use of SBRT and atezo. Collaboration between @MoffittRadOnc @MoffittGYNONC @OhioStateRadOnc 🤝 @OncoAlert
Can PD-L1 negative cervical cancer respond to immunotherapy? At #ASCO25, Kamran Ahmed, MD, (@KAhmedMD) presents phase II results of SBRT + atezolizumab in metastatic cervical cancer, showing responses even in PD-L1 negative tumors. Read more: bit.ly/3HyjnOZ…
Congrats, Dr. Upadhyay! @MoffittRadOnc
🔦Spotlight time! Introducing our newest Associate Editor @aiims2738 ! Raj submitted numerous great cases to eContour, making him the perfect fit for Associate Editor ➕ he's chock full of great ideas for the future! Welcome to the team, Raj!👏
Key points of the article: - #Hypofractionated stereotactic #ReIrradiation in combination with nivolumab, ipilimumab, and bevacizumab in patients with recurrent bevacizumab-naïve #HighGradeGlioma is safe. - The median overall survival was 15.6 months bit.ly/3GbAIwO
Grateful for the opportunity to work with this amazing team trying to find more treatment options for patients with recurrent high-grade gliomas!🧠 @MoffittNews @MoffittRadOnc @EditorNeuro @NeuroOnc doi.org/10.1093/noajnl…
#FollowFriday Meet Stephen Rosenberg, MD (@SA_Rosenberg), a thoracic oncologist in the radiation department and the Director of Adaptive Radiotherapy. His clinical focus is the treatment of thoracic malignancies, and his research explores the combination of radiation therapy with…
Great to be speaking at MRinRT conference with great physicians, physicists and colleagues ! Phenomenal work being done! @MoffittNews @MoffittRadOnc #radonc
🎙️ In honor of #HeadandNeckCancerAwarenessMonth, we’re spotlighting a new podcast episode of On Target: Logistics of Radiation Therapy in the Treatment of Head & Neck Cancers. 🎧 Listen now: astro.org/podcasts @RadOncDoc_Niema @EdinaWangMD @ASTRO_org @spohnc_1 @hncalliance
Received this letter today. Extremely honored to join this laser-focused group of clinicians/scientists/advocates that work tirelessly to eradicate #bladdercancer. Much to learn & much to do for our patients. Thank you @IBCG_BladderCA for the opportunity.
Welcome to Moffitt!
Congratulations to the new members of our #RadOnc family here at @MoffittNews 🫶🏽🔥
Thrilled you are joining us! @MoffittNews @JessicaFrakesMD @KOSJ12
Congratulations to the new members of our #RadOnc family here at @MoffittNews 🫶🏽🔥
Congratulations!
Congratulations to the new members of our #RadOnc family here at @MoffittNews 🫶🏽🔥
Congratulations to the new members of our #RadOnc family here at @MoffittNews 🫶🏽🔥
